SecBot SecBot

NRIX drug pipeline

Nurix Therapeutics, Inc. · 5 rated drugs
$15.48
−0.8% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
5
1 bullish · 4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
Time to market3-5 years (Phase 3 trials starting summer 2026; potential accelerated approval pathway via pivotal Phase 2 data could compress timeline)

bexobrutideg Updated Jul 9

What to watch

The Roche deal ($700M upfront, up to $2.3B total) already provided the major derisking catalyst, the stock surged ~70% on the June 8 announcement. Watch for HSR antitrust clearance (expected Q3 2026), Phase 3 trial initiation in CLL this summer, and any early data from planned Phase 2 starts in autoimmune (CSU) and neurology (MS). Analyst consensus is Strong Buy with mean PT of $31.44, but the stock already reflects significant partnership premium, new upside will require compelling Phase 2/3 data execution, not just partnership validation.

Bull case
  • Transformative Roche partnership provides $700M upfront, up to $2.3B total, validating the platform, eliminating near-term dilution risk, and providing a 50/50 U.S. profit share (Nurix press release / Reuters / Roche media release).
  • Impressive Phase 1 data: 83% ORR and 22.1-month median PFS in heavily pretreated CLL patients who failed both BTK inhibitors and BCL-2 inhibitors (ASH 2025 / EHA 2026 presentations).
  • CNS-penetrant property opens larger market opportunities in neurology (multiple sclerosis) and immunology (chronic spontaneous urticaria) beyond oncology, estimated total addressable market of ~$48B by 2030 (Nurix 8-K filing analysis).
Bear case
  • Roche partnership already priced in, stock surged ~70% premarket on the June 8 announcement; much of the upside may already be reflected at ~$24.69.
  • Phase 3 trial vs Lilly's already-approved Jaypirca (pirtobrutinib) is a high-risk binary, Jaypirca has already demonstrated superiority over ibrutinib in Phase 3 and has a multi-year commercial head start.
  • BTK degrader competition is intensifying: BeiGene's BGB-16673 and AbbVie's candidate are also in clinical development; this is a crowded, well-funded target space.
● neutral
Impact
PhasePhase 1
Time to marketEstimated 6-8+ years, if successful. Still in Phase 1; inflammation/immunology programs typically take years to reach approval.

GS-6791 irak4 degrader gs-6791 Updated Jul 9

What to watch

GS-6791 is a minor piece of the NRIX story. Investors should watch for Phase 1 healthy-volunteer safety/PK data from Gilead, which could inform Nurix's decision on opting into a 50/50 U.S. profit share. However, the stock's near-term trajectory is dominated by bexobrutideg (BTK degrader) and the Roche collaboration, GS-6791 is not a standalone catalyst for NRIX.

Bull case
  • First-in-class potential: GS-6791 is one of the few IRAK4 degraders to reach clinical testing, and degradation may achieve deeper, more sustained pathway blockade versus traditional IRAK4 kinase inhibitors, an approach Kymera/Sanofi is also pursuing (KT-485).
  • Large market opportunity: Targets multi-billion-dollar markets in inflammation, rheumatoid arthritis (~$25B+) and atopic dermatitis (~$10B+).
  • Gilead bears all development costs and has committed resources; Nurix receives a $20M option fee, up to $425M in milestones, and retains a 50/50 U.S. profit-share option after Phase 1.
Bear case
  • Very early-stage (Phase 1 in healthy volunteers), clinical failure rates in Phase 1 are high, and safety/PK in humans hasn't been demonstrated yet.
  • Competitive landscape: Kymera Therapeutics/Sanofi have a competing IRAK4 degrader (KT-485) advancing toward the clinic, while Pfizer and others have IRAK4 kinase inhibitors in development.
  • Dilution risk: GS-6791 is Gilead-led; Nurix has no control over development pace or go/no-go decisions. If Phase 1 data disappoints, Gilead may halt the program.
● neutral
Impact
PhasePhase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
Time to marketUnknown — still in Phase 1a dose-escalation with no Phase 2/3 timelines set. If successful through Phase 1b, a registrational path would be several years away.

NX-1607 Updated Jul 9

What to watch

NX-1607 is an early-stage, first-in-class asset that is not the primary value driver for NRIX (that's bexobrutideg, which Roche partnered for up to $2.3B). Phase 1a data showing 49.3% DCR is encouraging but too early for pivotal conclusions. Watch for when the company announces Phase 1b expansion plans or presents updated data at a medical conference, no specific date is set. For now, NX-1607 is a pipeline free option on a novel immuno-oncology mechanism, not a standalone reason to trade NRIX.

Bull case
  • First-in-class CBL-B inhibitor with a novel mechanism (intramolecular glue) that differentiates it from PD-1/PD-L1 checkpoint inhibitors and could address immunotherapy-resistant tumors.
  • Phase 1a data showed a 49.3% disease control rate in 82 heavily pretreated patients, with a confirmed partial response in MSS CRC (micro-satellite stable colorectal cancer), a tumor type that typically does not respond to checkpoint inhibitors, with one patient treated for 27 months.
  • No other CBL-B inhibitor has advanced further in clinical trials globally (HotSpot Therapeutics' HST-1011 is also Phase 1), positioning NX-1607 as a potential first-mover if it advances.
Bear case
  • NX-1607 is still in very early-stage Phase 1a with no Phase 1b expansion initiated yet, the drug is years from any potential approval and has no guarantee of advancing past Phase 1.
  • No hard, dated catalyst exists for NX-1607 in the next ~12 months. The company is simply 'reviewing data to determine next steps,' creating an indefinite timeline.
  • NX-1607 is not Nurix's primary value driver, the stock is overwhelmingly driven by the Roche-partnered bexobrutideg (BTK degrader) story, so NX-1607 developments may have limited impact on share price.
● neutral
Impact
PhasePhase 1
Time to marketUnlikely before 2028-2029 if successful. Still in Phase 1 with no pivotal trial design disclosed. The trial's final completion is estimated at May 2027.

zelebrudomide Updated Jul 9

What to watch

Zelebrudomide is a secondary pipeline asset at Nurix. The stock's primary value driver is bexobrutideg (NX-5948) and its recently announced Roche partnership ($700M upfront). Watch for any Phase 1 data updates from zelebrudomide at hematology conferences (ASH/EHA), but this single drug alone will not meaningfully move the stock given the company's $1.24B pro-forma cash position and broader pipeline focus.

Bull case
  • First-in-class dual mechanism, zelebrudomide simultaneously degrades BTK (a validated cancer target) and Ikaros/Aiolos (immune-modulatory proteins), potentially offering a double-hit against B-cell malignancies that have stopped responding to conventional BTK inhibitors.
  • Early Phase 1 data showed a 40.7% ORR in heavily pretreated CLL patients, with 2 complete responses (ongoing at 9.2 and 11.8 months) in NHL patients, meaningful activity in a patient population that had progressed on prior BTK inhibitors.
  • The optimized R-diastereomer formulation (post-clinical-hold) may improve the drug's therapeutic index and efficacy profile.
Bear case
  • Zelebrudomide has been eclipsed by bexobrutideg (NX-5948) as Nurix's lead BTK degrader, the Roche partnership makes clear that bexobrutideg is the priority, and zelebrudomide may face resource reallocation or deprioritization.
  • The 5-month partial clinical hold (Nov 2023 - Mar 2024) for manufacturing issues delayed enrollment and raised questions about drug-product consistency; the program is restarting months behind schedule.
  • Still early Phase 1 with no registrational trial design or regulatory guidance, a very long path to commercialization, likely 2028+ if successful.
● neutral
Impact
PhasePreclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
Time to marketUnknown — still in preclinical/IND-enabling stage with Phase 1 trial authorized but not recruiting; likely 5-7+ years from potential approval if successful

NX-3911 Updated Jul 9

What to watch

NX-3911 is a minor, partnered pipeline component for NRIX. Investors should focus on the company's wholly-owned BTK degrader bexobrutideg (partnered with Roche, $700M upfront) and other pipeline catalysts for stock movement. NX-3911 specific news (Phase 1 initiation or early data) would likely drive only modest, indirect moves via milestone optics.

Bull case
  • STAT6 is a validated, once-'undruggable' target in a large market (atopic dermatitis, asthma) with blockbuster potential, oral degrader approach may offer best-in-class profile.
  • Sanofi's exercise of the license option validates NX-3911 preclinically; Nurix retains right to opt into 50/50 U.S. profit share after clinical proof of concept, preserving upside.
  • Nurix's $1.24B pro-forma cash balance (post-Roche deal) removes dilutive financing risk; the Sanofi collaboration provides non-dilutive funding for NX-3911 development.
Bear case
  • NX-3911 is years behind Kymera's KT-621, which completed Phase 1b with 98% STAT6 degradation, has FDA Fast Track, and is already in Phase 2b atopic dermatitis with enrollment completed, Phase 3 targeted by mid-2027.
  • As a partnered program with Sanofi, positive data benefits NRIX only indirectly through milestones and the opt-in right; Sanofi controls development timelines and could deprioritize.
  • Nurix's pipeline presentation as of mid-2026 still lists NX-3911 as 'preclinical stage', and the Phase 1 trial has not yet started recruiting, development is still very early and timelines are uncertain.